Potential Phytocompounds to Inhibit Human Polo-Like Kinase 1 in Cancer Therapy

被引:0
|
作者
Davis, Sangeetha P. [1 ]
Baby, Bincy [1 ]
Vipin, A. M. [1 ]
Kumar, Mala S. [1 ]
Nazeem, P. A. [1 ]
机构
[1] Kerala Agr Univ, Coll Hort, Bioinformat Ctr, IT BT Complex,Vellanikkara PO, Trichur 680656, Kerala, India
来源
RESEARCH JOURNAL OF PHARMACEUTICAL BIOLOGICAL AND CHEMICAL SCIENCES | 2015年 / 6卷 / 06期
关键词
Discovery Studio 4.0; Human polo-like kinases; Molecular docking; Phytocompounds;
D O I
暂无
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cancer is a potential fatal disease characterized by the uncontrolled growth and spread of abnormal cells. Polo-like kinases (Plks) are serine/threonine protein kinases which play critical role in regulating cell cycle. Deregulated expression of Plks is detected in many types of cancer and is associated with oncogenesis. Though there are five Plk homologous, Plk 1 is identified as the best target to defend uncontrolled cell growth. Natural compounds from plant resource are being exploited recently on a large scale for treating various diseases. The aim of this study is to identify the inhibitory activity of selected phytochemicals on Plk 1 protein so as to develop effective drugs based on natural compounds. In silico docking analysis is a successful way of screening molecules so as to confirm their inhibitory activity against respective targets. About 574 phytocompounds of various conformations were docked with the target protein Plk 1 using the software Discovery Studio version 4.0. The most effective ones were identified based on interaction energy and docking score. Phytocompounds such as ferulic acid, caffeic acid and N-methyltyramine from the common medicinal plants like Curcuma longa, Pseudarthria viscida and Wrightia tinctoria showed strong anticancer activity through the suppression of Plk 1.
引用
收藏
页码:1257 / 1263
页数:7
相关论文
共 32 条
  • [1] Computational Investigation of Polo-like Kinase 1 (plk1): Inhibitive Potential of Benzimidazole-Carbonamide Derivatives for Cancer Treatment
    Ipinloju, N.
    Balogun, T. A.
    Ibrahim, A.
    Adeyemo, M. A.
    Esan, T. O.
    Emmanuel, A. V.
    Bello, K. A.
    Omiyeniyi, G. D.
    Oyeneyin, O. E.
    PHYSICAL CHEMISTRY RESEARCH, 2024, 12 (02): : 333 - 348
  • [2] Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach
    Kumar, Manoj
    Pydi, Sai Prasad
    Sharma, Sujata
    Singh, Tej P.
    Kaur, Punit
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2014, 51 : 104 - 112
  • [3] Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1
    Sun, Juan
    Liu, Han-Yu
    Xu, Ruo-Fei
    Zhu, Hai-Liang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (24) : 6581 - 6588
  • [4] QSAR, molecular docking studies of thiophene and imidazopyridine derivatives as polo-like kinase 1 inhibitors
    Cao, Shandong
    JOURNAL OF MOLECULAR STRUCTURE, 2012, 1020 : 167 - 176
  • [5] Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1
    Chen, Yanhong
    Yu, Zhiyan
    Liu, Yu
    Lin, Tongyuan
    Sun, Huiyong
    Yang, Dasong
    Jiang, Cheng
    BIOORGANIC CHEMISTRY, 2018, 81 : 278 - 288
  • [6] In silico study on interaction between human polo-like kinase 1 and cyanobacterial sheath pigment scytonemin by molecular docking approach
    Pathak, Jainendra
    Mondal, Soumila
    Ahmed, Haseen
    Rajneesh
    Singh, Shailendra P.
    Sinha, Rajeshwar P.
    BIOINTERFACE RESEARCH IN APPLIED CHEMISTRY, 2019, 9 (05): : 4374 - 4378
  • [7] An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication
    Rizvi, Syed Mohd. Danish
    Alshammari, Abdulaziz Arif A.
    Almawkaa, Waleed Abdullah
    Ahmed, Abo Bakr F.
    Katamesh, Ahmed
    Alafnan, Ahmed
    Almutairi, Tariq J.
    Alshammari, Rakan F.
    3 BIOTECH, 2019, 9 (03)
  • [8] An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication
    Syed Mohd. Danish Rizvi
    Abdulaziz Arif A. Alshammari
    Waleed Abdullah Almawkaa
    Abo Bakr F. Ahmed
    Ahmed Katamesh
    Ahmed Alafnan
    Tariq J. Almutairi
    Rakan F. Alshammari
    3 Biotech, 2019, 9
  • [9] QSAR study of tetrahydropteridin derivatives as polo-like kinase 1(PLK1) Inhibitors with molecular docking and dynamics study
    Sharma, S.
    Sindhu, J.
    Kumar, P.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2023, 34 (02) : 91 - 116
  • [10] Structural insights into the inhibitor binding and new inhibitor design to Polo-like kinase-1 Polo-box domain using computational studies
    Abdullah, Maaged
    Guruprasad, Lalitha
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2019, 37 (13) : 3410 - 3421